Christopher F. Nicodemus, MD FACP, is Founder, President and Chief Scientific Officer of AIT Strategies. He served as Chairman and Chief Scientific Officer of Advanced Immune Therapeutics, Inc., from 2008-2012. Dr. Nicodemus received undergraduate training at Harvard College and received his MD degree Upstate Medical University in Syracuse, NY. He trained in Internal Medicine and completed a Research and Clinical fellowship in the laboratory of K Frank Austen, Department of Rheumatology and Clinical Immunology at Brigham and Women’s Hospital, Harvard Medical School, Boston. He held various research and clinical appointments at Harvard while pursuing a career in biotechnology. He has held executive positions at Pfizer, ImmuLogic, Diatide, AltaRex, United Therapeutics and Advanced Immune Therapeutics, Inc. He is a member of Alpha Omega Alpha and a fellow of the American College of Physicians.
His career has been dedicated to research into immune modulation and experimental medicine with a focus on the application of cellular and molecular biology to clinical immunology and drug development. Early efforts using peptides as immunogens, led to the study of T-cell reactive epitopes and tolerance induction, which subsequently evolved into study of antibodies to elicit immunity.
An early clinical focus in allergy, autoimmunity, and asthma has more recently shifted to a focus on tumor immunology, with an emphasis on ovarian cancer immunobiology and immunotherapy. Dr. Nicodemus has conceived, designed and executed and published numerous clinical studies, holds multiple patents, and has extensive regulatory experience with the successful completion of three New Drug Applications.
Dr. Nicodemus actively publishes and lectures in the field of translational immunology and Immuno-Oncology. IgE technology developed at Advanced Immune Therapeutics, Inc. has been acquired by Quest Pharmatech, Inc. AIT Strategies is an active participant in the continuing development of both IgG and IgE technologies as a component of immunotherapeutic approaches for the treatment of cancer in association with Quest PharmaTech and partners. The recent progress in the development of checkpoint inhibitors to unleash latent immunity in some cancer victims has resulted in previously unachievable responses and even cures in patients with advanced solid malignancies. The challenge for the scientific community is now to extend this initial success using techniques to enhance the percentage of patients able to respond to checkpoint therapy. AIT Strategies believes that selective and scheduled combinations utilizing this antibody technology can achieve that objective. Working in collaboration with Quest PharmaTech, Shenzhen Hepalink and several associated partners, AIT Strategies will advance these technologies in association with the newly formed entity OncoQuest, Inc. and its Chinese joint venture partner, OncoVent.